Paget's Disease of Bone

1. Clinical Overview

Summary

Paget's disease of bone (PDB) is a chronic, focal disorder of bone remodeling characterized by excessive and disorganized bone turnover. The fundamental pathology involves abnormal osteoclast activity leading to accelerated bone resorption, followed by compensatory but chaotic osteoblastic bone formation. This produces structurally weak, enlarged, and highly vascular bones that are prone to deformity, fracture, and pain.

The disease typically affects individuals over 55 years of age and is frequently asymptomatic, discovered incidentally through elevated serum alkaline phosphatase (ALP) or characteristic radiological findings. When symptomatic, patients present with bone pain, skeletal deformity (particularly bowing of weight-bearing long bones), and complications related to bone enlargement including hearing loss, spinal stenosis, and secondary osteoarthritis.

The hallmark biochemical finding is an isolated elevation of serum ALP (reflecting increased osteoblastic activity), with serum calcium and phosphate typically remaining normal unless the patient is immobilized. Radiologically, affected bones show a mixture of lytic and sclerotic changes, cortical thickening, and trabecular coarsening. The skull classically demonstrates the "cotton-wool" appearance of patchy sclerosis.

Treatment with intravenous bisphosphonates (zoledronic acid) or oral bisphosphonates (risedronate) effectively suppresses bone turnover, normalizes ALP, reduces pain, and may prevent complications. The most feared complication is malignant transformation to osteosarcoma, which occurs in less than 1% of patients but carries a poor prognosis. Other significant complications include pathological fractures, high-output cardiac failure (due to increased bone vascularity), and neurological sequelae from bone expansion.

Key Facts

• Pathophysiology: Abnormal osteoclasts → excessive bone resorption → chaotic osteoblastic formation → structurally weak "woven bone"
• Typical Patient: Age > 55 years; male predominance (M:F 1.8:1); often asymptomatic (70-80%)
• Key Biochemistry: Isolated raised ALP (often markedly elevated); calcium and phosphate normal (unless immobilized)
• Most Commonly Affected Sites: Pelvis (most common) > spine > femur > skull > tibia
• Classic Imaging: X-ray shows mixed lytic/sclerotic lesions, cortical thickening, "cotton-wool skull"
  • "blade of grass" sign (lytic wedge in long bones)
• First-Line Treatment: Zoledronic acid 5mg IV single infusion (or risedronate 30mg PO daily for 2 months)
• Serious Complication: Osteosarcoma (less than 1%; sudden increase in pain/swelling, rapidly rising ALP)

Clinical Pearls

"Raised ALP, Normal Calcium": The classic biochemical signature. Markedly elevated ALP reflects increased osteoblastic activity. Calcium and phosphate remain normal unless the patient becomes immobilized (leading to hypercalcemia from unopposed bone resorption).

"Cotton-Wool Skull": The pathognomonic X-ray appearance of skull Paget's—areas of patchy sclerosis interspersed with lytic regions give a cotton-wool-like appearance on plain radiograph.

"Sabre Tibia": Anterior bowing of the tibia is a characteristic deformity in long-standing Paget's disease, resembling the curve of a cavalry sabre.

"Increased Hat Size": Patients with skull involvement may notice their hats no longer fit due to progressive skull thickening and enlargement—a simple but diagnostically useful historical feature.

"Warm Bone": Affected bones may feel warm to palpation due to markedly increased vascularity, and in severe polyostotic disease, this can rarely precipitate high-output cardiac failure.

"Single Dose Treatment": A single infusion of zoledronic acid 5mg provides sustained disease suppression for several years in most patients, with ALP normalization in approximately 90% and symptom improvement in the majority.

---

2. Epidemiology

Prevalence and Geographic Distribution

Paget's disease exhibits marked geographic variation, being most prevalent in populations of Anglo-Saxon descent. In the United Kingdom, prevalence is approximately 2-3% in individuals over 55 years of age, rising to 5-10% in those over 80 years. [1] The disease is particularly common in certain regions of England (Lancashire, Yorkshire), France, Australia, and New Zealand.

The disease is rare in Asian, African, and Scandinavian populations. Within the United States, there is higher prevalence among individuals of European ancestry compared to other ethnic groups.

Notably, both the incidence and severity of Paget's disease appear to be declining in many countries over recent decades, for reasons that remain unclear but may relate to environmental factors or changes in infectious disease exposure during childhood. [2]

Age and Sex Distribution

• Age: Rare before 40 years; incidence increases with age, peaking in the 7th-8th decades
• Sex: Male predominance with M:F ratio approximately 1.8:1 [3]
• Familial Clustering: 15-30% of patients have a positive family history, suggesting genetic predisposition [4]

Temporal Trends

Multiple studies have documented a declining incidence and severity of Paget's disease over the past 30-40 years. Proposed explanations include:

• Reduced exposure to childhood paramyxovirus infections (measles vaccination)
• Environmental factor changes
• Improved nutrition and vitamin D status
• True reduction in genetic susceptibility expression

---

3. Aetiology and Pathophysiology

Genetic Factors

Exam Detail: SQSTM1 Mutations: The most well-established genetic association is with mutations in the SQSTM1 gene (sequestosome 1, also known as p62), located on chromosome 5q35. Mutations in SQSTM1 account for approximately 10-50% of familial cases and 5-10% of sporadic cases. [5]

The SQSTM1 protein functions as a scaffolding protein involved in osteoclast signaling, autophagy, and NF-κB activation. Mutations lead to:

• Enhanced osteoclast differentiation
• Increased osteoclast survival
• Hyperresponsiveness to RANK-ligand (RANKL) signaling
• Resistance to apoptosis

Other rare genetic associations include mutations in:

• VCP (valosin-containing protein): Causes inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD syndrome)
• TNFRSF11A (RANK gene): Rare familial cases with early-onset severe disease
• TNFRSF11B (osteoprotegerin gene): Juvenile Paget's disease (distinct entity)

Familial Clustering: 15-30% of patients report a positive family history. Autosomal dominant inheritance with incomplete penetrance is observed in familial cases. Affected individuals may develop disease at younger ages and with greater severity.

Environmental and Viral Hypotheses

Exam Detail: The paramyxovirus hypothesis proposes that chronic infection with a measles-like paramyxovirus triggers abnormal osteoclast activity in genetically susceptible individuals. Evidence supporting this includes:

• Detection of paramyxovirus-like inclusions in pagetic osteoclasts on electron microscopy
• Presence of measles virus nucleocapsid protein transcripts in pagetic bone specimens
• Geographic clustering consistent with infectious patterns
• Declining incidence coinciding with widespread measles vaccination

However, this hypothesis remains controversial:

• Other studies have failed to replicate viral detection
• No live virus has been cultured from pagetic bone
• The mechanism by which chronic viral infection would produce focal bone lesions is unclear

Alternative environmental factors proposed include:

• Vitamin D deficiency during bone development
• Exposure to specific toxins or heavy metals
• Socioeconomic factors correlating with disease prevalence

Pathophysiology: The Three Phases

Paget's disease progresses through three overlapping phases:

1. Lytic (Osteoclastic) Phase

• Dominant process: Excessive bone resorption by abnormal osteoclasts
• Osteoclast characteristics:
  • Markedly enlarged (10-100 times normal size)
  • Increased number of nuclei (up to 100 vs. 5-10 in normal osteoclasts)
  • Hyperresponsive to RANKL signaling
  • Increased lifespan and resistance to apoptosis
• Radiological appearance: Advancing lytic wedge ("blade of grass" or "flame-shaped" lesion) in long bones; osteoporosis circumscripta in the skull
• Biochemistry: Rising bone resorption markers (urinary/serum CTX, NTX)

2. Mixed Phase

• Dominant process: Simultaneous resorption and chaotic bone formation
• Osteoblastic response: Attempts to compensate for excessive resorption but produces disorganized bone architecture
• Bone structure: "Woven bone" with irregular cement lines (mosaic pattern on histology)
• Radiological appearance: Mixed lytic and sclerotic areas, cortical thickening, trabecular coarsening
• Biochemistry: Markedly elevated ALP (osteoblastic activity) and bone resorption markers

3. Sclerotic (Osteoblastic) Phase

• Dominant process: Predominantly bone formation with reduced resorption
• Bone characteristics:
  • Dense, sclerotic bone
  • Disorganized architecture (woven rather than lamellar bone)
  • Structurally weak despite increased density
  • Markedly increased vascularity
• Radiological appearance: Dense sclerotic bone, cortical thickening, bone enlargement and deformity
• Biochemistry: Persistently elevated ALP; bone resorption markers may normalize

Consequences of Abnormal Bone Remodeling

---

4. Clinical Presentation

Asymptomatic Disease (70-80% of Cases)

The majority of patients with Paget's disease are asymptomatic and diagnosed incidentally through:

• Elevated serum ALP on routine biochemistry
• Incidental radiological findings (X-ray performed for unrelated reasons)
• Investigation of a family history of Paget's disease

Symptomatic Disease

When symptomatic, clinical manifestations relate to:

1. Bone pain and deformity
2. Complications of bone enlargement
3. Fractures and arthritis
4. Metabolic consequences

Bone Pain

• Character: Deep, aching, poorly localized bone pain
• Timing: Worse at night; may wake patient from sleep
• Location: At sites of pagetic involvement (pelvis, spine, femur, tibia, skull)
• Mechanism: Increased bone vascularity, microfractures, periosteal stretching, secondary arthritis
• Severity: Ranges from mild discomfort to severe, disabling pain

Skeletal Deformity

Complications of Bone Enlargement

Neurological Complications:

• Hearing loss (most common neurological complication):
  • "Mechanism: Compression of cranial nerve VIII in internal auditory meatus, ossicle involvement, cochlear dysfunction"
  • May be conductive, sensorineural, or mixed
  • Typically progressive and irreversible
• Spinal stenosis:
  • Vertebral expansion compressing spinal cord or nerve roots
  • Presents with radiculopathy, myelopathy, claudication symptoms
  • Thoracic spine involvement may cause spastic paraparesis
• Cranial nerve compression:
  • "Optic nerve (rare): Visual impairment"
  • "Other cranial nerves: Facial pain, diplopia"
• Basilar invagination (rare):
  • Upward migration of odontoid peg through foramen magnum
  • Brainstem compression, hydrocephalus

Cardiovascular Complications:

• High-output cardiac failure:
  • "Mechanism: Markedly increased bone vascularity creates arteriovenous shunting"
  • Rare; occurs only in severe polyostotic disease (> 15-35% skeletal involvement)
  • "Presents with features of heart failure: dyspnea, peripheral edema, elevated JVP"
  • Cardiac output may increase to 2-3 times normal
  • Affected bones feel warm to palpation

Fractures

• Pathological fractures: Occur in structurally weakened pagetic bone
• Typical pattern: Transverse "chalk-stick" fractures of long bones (femur, tibia)
• Location: Often occur through lytic lesions or at the junction of pagetic and normal bone
• Healing: May be delayed; callus formation can be excessive
• Insufficiency fractures: Incomplete fractures (microfractures) causing chronic pain

Secondary Osteoarthritis

• Mechanism: Bone deformity and biomechanical stress lead to accelerated cartilage degeneration
• Common sites: Hip (femoral head and acetabular involvement), knee
• Clinical features: Joint pain, stiffness, reduced range of motion
• Severity: May necessitate joint replacement surgery

Sites of Involvement (in Order of Frequency)

1. Pelvis (60-70%): Most commonly affected site; often asymptomatic or causes hip/sacroiliac pain
2. Lumbar spine (40-50%): Back pain, spinal stenosis, nerve root compression
3. Femur (30-40%): Bowing deformity, hip pain (secondary OA), fractures
4. Skull (25-35%): Enlargement, hearing loss, headache, "cotton-wool" appearance on X-ray
5. Tibia (25-35%): Anterior bowing (sabre tibia), fractures
6. Thoracic spine (15-25%)
7. Clavicle, ribs, humerus (less common)

Distribution Patterns:

• Monostotic (15-30%): Single bone involved
• Polyostotic (70-85%): Multiple bones involved; typically asymmetric and focal

---

5. Clinical Examination

General Inspection

• Gait assessment: Antalgic gait, leg-length discrepancy, waddling gait (bilateral hip involvement)
• Posture: Kyphosis, forward flexion, head tilt
• Skeletal deformity: Obvious bowing of lower limbs, asymmetry

Regional Examination

Lower Limbs

Inspection:

• Anterior bowing of tibia (sabre tibia)
• Lateral bowing of femur
• Leg-length discrepancy (measure true and apparent leg length)
• Muscle wasting (disuse atrophy from pain)

Palpation:

• Warmth over affected bones (increased vascularity)
• Bony tenderness at sites of disease activity
• Thickening/enlargement of affected bones
• Temperature comparison with contralateral limb

Movement:

• Hip/knee range of motion (assess for secondary osteoarthritis)
• Pain on movement
• Fixed flexion deformity

Special Tests:

• Trendelenburg test (hip involvement)
• Thomas test (hip flexion contracture)

Skull and Face

Inspection:

• Skull enlargement (measure occipitofrontal circumference if indicated)
• Frontal bossing
• Facial asymmetry

Palpation:

• Skull thickening
• Warmth
• Tenderness

Cranial Nerve Examination:

• CN II (Optic): Visual acuity, visual fields, fundoscopy (optic atrophy from compression)
• CN VIII (Vestibulocochlear): Hearing assessment (whispered voice, Rinne and Weber tests for conductive vs. sensorineural loss)
• Other cranial nerves as indicated

Spine

Inspection:

• Thoracic kyphosis
• Loss of lumbar lordosis
• Scoliosis

Palpation:

• Spinous process tenderness
• Paraspinal muscle spasm

Neurological Examination:

• Motor: Tone, power, reflexes (assess for upper motor neuron signs in spinal stenosis/cord compression)
• Sensory: Dermatomal distribution (radiculopathy)
• Gait: Assess for spastic gait, sensory ataxia

Examination for Complications

Cardiovascular System:

• Signs of high-output cardiac failure:
  • Tachycardia
  • Bounding pulse (high stroke volume, low diastolic pressure)
  • Elevated JVP
  • S3 gallop
  • Peripheral edema
  • Warm extremities

Hearing Assessment:

• Whispered voice test at 60cm
• Rinne test: Air conduction vs. bone conduction
• Weber test: Lateralization

Neurological Assessment:

• Lower limb neurology for spinal stenosis/radiculopathy
• Gait assessment for claudication symptoms
• Upper motor neuron signs (spinal cord compression)

Examination Pearls for MRCP/PACES

"Feel the Warmth": Always palpate affected bones and compare temperature with contralateral side. Pagetic bone is characteristically warm due to increased vascularity—this is a valuable discriminatory sign from other metabolic bone diseases.

"Measure the Hat": In suspected skull involvement, asking about hat size (or directly measuring occipitofrontal circumference and comparing with old photographic records) provides useful temporal information.

"Listen for Heart Failure": In polyostotic disease, always examine the cardiovascular system for high-output cardiac failure—this is a rare but serious complication that is easily missed.

---

6. Differential Diagnosis

Approach to the Patient with Isolated Raised ALP

Paget's disease is a common cause of isolated elevated ALP with normal calcium and phosphate. The differential diagnosis includes:

Approach to the Patient with Bone Pain and Deformity

Skull Lesions on Imaging

---

7. Investigations

Biochemical Investigations

Serum Alkaline Phosphatase (ALP)

• Hallmark biochemical finding: Isolated elevation of total ALP
• Degree of elevation: May be mildly elevated (1.5-2× ULN) to markedly elevated (> 10× ULN)
• Correlation: Degree of elevation correlates with extent and activity of disease
• Isoenzyme analysis: Bone-specific ALP (BALP) confirms skeletal origin; useful if liver disease suspected
• Monitoring: Serial ALP levels used to assess disease activity and response to treatment
• Treatment target: Aim for normalization or ≥75% reduction from baseline

Interpretation Pearls:

• ALP may be normal in monostotic disease with low activity
• Liver disease may coexist—check GGT and liver function tests
• Pregnancy and growing children have elevated ALP (physiological)

Calcium and Phosphate

• Calcium: Typically normal in active disease
• Hypercalcemia: May occur if patient becomes immobilized (unopposed bone resorption exceeds formation)
• Phosphate: Typically normal
• Interpretation: Normal calcium/phosphate distinguishes Paget's from hyperparathyroidism (high calcium) and osteomalacia (low phosphate)

Bone Turnover Markers

Not routinely required but may be useful in specific contexts:

Radiological Investigations

Plain Radiography

First-line imaging to confirm diagnosis and assess extent.

Characteristic Features:

Site-Specific Features:

• Skull: Cotton-wool appearance (patchy sclerosis); osteoporosis circumscripta (lytic); skull thickening; basilar invagination (rare)
• Pelvis: Thickening of iliopectineal line ("brim sign"); acetabular protrusion; sclerosis; coarse trabeculae
• Spine: "Picture frame" vertebra (thickened cortical outline with central lucency); "ivory vertebra" (uniform sclerosis); vertebral enlargement
• Long bones: Cortical thickening; anterior bowing (tibia); V-shaped lytic wedge; transverse fractures

Bone Scintigraphy (Technetium-99m Bone Scan)

Indications:

• Determine extent of skeletal involvement (polyostotic vs. monostotic)
• Identify asymptomatic sites of disease
• Assess disease activity
• Pre-operative planning (orthopedic surgery)

Findings:

• Intense tracer uptake at sites of pagetic involvement
• Typically shows more extensive disease than plain radiography
• Does not differentiate Paget's from other causes of increased bone turnover (e.g., metastases, fracture, infection)

Interpretation:

• Extent of uptake on bone scan correlates with disease activity and ALP level
• Useful baseline investigation to assess polyostotic disease

Cross-Sectional Imaging (CT/MRI)

Indications:

• Suspected complications:
  • Spinal stenosis or cord compression (MRI)
  • Basilar invagination (CT/MRI)
  • Malignant transformation (MRI)
• Pre-operative planning for orthopedic procedures
• Unclear diagnosis on plain radiography

CT Findings:

• Detailed assessment of cortical thickening and trabecular architecture
• Bone expansion and deformity
• Spinal canal narrowing

MRI Findings:

• Marrow signal changes (heterogeneous)
• Spinal cord compression or nerve root impingement
• Soft tissue component (raises suspicion for malignant transformation)
• Contrast enhancement in active disease

Additional Investigations

Genetic Testing

Not routinely indicated but may be considered in:

• Young-onset disease (less than 40 years): Suspect SQSTM1 or other genetic mutations
• Strong family history: Genetic counseling and cascade screening
• Atypical features: Exclude rare genetic syndromes (e.g., VCP-related IBMPFD syndrome)

Hearing Assessment

Indications: Skull involvement, patient reporting hearing difficulty

Tests:

• Pure tone audiometry
• Tympanometry (if conductive component suspected)
• Brainstem auditory evoked potentials (assess neural pathway)

Cardiac Assessment

Indications: Extensive polyostotic disease (> 35% skeletal involvement), symptoms of heart failure

Tests:

• Echocardiography (assess cardiac output, left ventricular function)
• ECG
• B-type natriuretic peptide (BNP) if heart failure suspected

Investigation Algorithm

┌─────────────────────────────────────────────────────────────┐
│   SUSPECTED PAGET'S DISEASE INVESTIGATION PATHWAY           │
├─────────────────────────────────────────────────────────────┤
│                                                             │
│  INITIAL PRESENTATION (e.g., isolated raised ALP)           │
│           ↓                                                 │
│  BIOCHEMISTRY:                                              │
│  • Serum ALP (total)                                        │
│  • Calcium, phosphate                                       │
│  • Bone-specific ALP (if liver disease suspected)           │
│  • Liver function tests (GGT, ALT, AST)                     │
│  • Renal function                                           │
│           ↓                                                 │
│  IMAGING:                                                   │
│  • Plain X-rays of symptomatic sites and pelvis             │
│  • If diagnosis confirmed → bone scan to assess extent      │
│           ↓                                                 │
│  DIAGNOSIS CONFIRMED                                        │
│  • Isolated raised ALP (bone origin)                        │
│  • Characteristic X-ray changes                             │
│  • Normal calcium/phosphate                                 │
│           ↓                                                 │
│  ASSESS COMPLICATIONS:                                      │
│  • Skull involvement → audiometry                           │
│  • Spinal involvement + neurology → MRI spine               │
│  • Polyostotic disease → echocardiography                   │
│  • Sudden pain increase/swelling → MRI (? sarcoma)          │
│           ↓                                                 │
│  TREAT AND MONITOR (see Management section)                 │
│                                                             │
└─────────────────────────────────────────────────────────────┘

---

8. Management

Indications for Treatment

Not all patients with Paget's disease require treatment. Treatment is indicated for:

1. Symptomatic disease:

   • Bone pain attributable to active Paget's disease
   • Neurological complications (hearing loss, radiculopathy, spinal stenosis)
   • Deformity causing functional impairment

2. Prevention of complications:

   • Disease in weight-bearing bones (risk of fracture or deformity)
   • Disease adjacent to major joints (risk of secondary osteoarthritis)
   • Disease at sites where complications would be serious (skull, spine)

3. Pre-operative preparation:

   • Elective orthopedic surgery on pagetic bone (reduce vascularity and surgical bleeding)

4. Hypercalcemia (if immobilized)

Asymptomatic disease without complications: Observation with periodic monitoring (ALP every 6-12 months) is appropriate.

Pharmacological Treatment

Bisphosphonates (First-Line)

Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and are the cornerstone of treatment.

Mechanism of Action:

• Bind to hydroxyapatite in bone
• Internalized by osteoclasts during bone resorption
• Inhibit farnesyl pyrophosphate synthase (in nitrogen-containing bisphosphonates)
• Induce osteoclast apoptosis and reduce bone turnover

First-Line Agent: Zoledronic Acid (Intravenous)

Pre-Treatment:

• Ensure adequate vitamin D status (25-OH vitamin D > 50 nmol/L)
• Correct hypocalcemia before administration
• Ensure adequate calcium and vitamin D intake (calcium 1000-1200mg/day, vitamin D 800-1000 IU/day)
• Adequate hydration before infusion

Adverse Effects:

• Acute phase reaction (flu-like symptoms, fever, myalgia, arthralgia) in ~30%; typically lasts 24-72 hours; reduced by paracetamol/NSAIDs and pre-hydration
• Hypocalcemia (especially if vitamin D deficient)
• Renal impairment (avoid if eGFR less than 35 mL/min)
• Atypical femoral fractures (rare, with long-term use)
• Osteonecrosis of the jaw (rare; risk increased with dental procedures, concomitant corticosteroids, cancer)

Alternative Agent: Risedronate (Oral)

Other Oral Bisphosphonates:

• Alendronate: 40mg daily for 6 months (less commonly used; inferior to risedronate and zoledronic acid)
• Pamidronate (IV): 60mg IV weekly for 6 weeks (alternative to zoledronic acid if not available)

Calcitonin (Historical Interest)

• Potent inhibitor of osteoclast activity
• Rarely used now: Replaced by bisphosphonates (superior efficacy, convenience)
• Potential role in patients intolerant of bisphosphonates (very rare)

Non-Pharmacological Treatment

Analgesia

• Simple analgesics: Paracetamol for mild bone pain
• NSAIDs: Effective for bone pain and secondary osteoarthritis; use with caution (GI, renal, cardiovascular risks)
• Opioids: Reserved for severe, refractory pain

Orthopedic Interventions

Indications:

• Fractures through pagetic bone
• Severe deformity with functional impairment
• Secondary osteoarthritis requiring joint replacement
• Spinal stenosis with neurological deficit

Considerations:

• Pre-operative bisphosphonate therapy (6 weeks to 3 months prior) reduces bone vascularity and surgical bleeding
• Increased risk of surgical bleeding in untreated patients
• Fracture healing may be delayed
• Joint replacement outcomes generally good, though technically challenging due to bone deformity

Common Procedures:

• Total hip replacement (secondary OA)
• Total knee replacement (secondary OA)
• Osteotomy (corrective surgery for deformity)
• Spinal decompression (for spinal stenosis with neurological compromise)

Hearing Aids

• For conductive or sensorineural hearing loss from skull involvement
• Bisphosphonate treatment does not reverse established hearing loss

Management of Complications

Hypercalcemia (Immobilization)

• Mechanism: Immobilization causes unopposed bone resorption exceeding formation
• Management:
  • Rehydration with IV saline
  • Mobilize patient as soon as possible
  • Bisphosphonate therapy (zoledronic acid 4mg IV) if severe
  • Calcitonin (rarely needed)

Pathological Fracture

• Orthopedic consultation
• Pre-operative bisphosphonate if surgery planned (reduce vascularity)
• Fracture fixation or arthroplasty as indicated
• Post-operative bisphosphonate to suppress disease activity

Spinal Stenosis/Neurological Compromise

• MRI spine to confirm diagnosis and assess extent
• Neurosurgical/Spinal surgical consultation
• Bisphosphonate therapy may slow progression but does not reverse established compression
• Decompressive surgery if progressive neurological deficit

High-Output Cardiac Failure

• Mechanism: Excessive bone vascularity creates arteriovenous shunting
• Management:
  • Standard heart failure therapy (diuretics, ACE inhibitors, beta-blockers)
  • Bisphosphonate therapy to reduce bone turnover and vascularity
  • May improve cardiac output in some patients [8]

Malignant Transformation (Osteosarcoma)

• Incidence: less than 1% of patients with Paget's disease
• Clinical clues:
  • Sudden increase in pain or swelling at site of pagetic bone
  • Rapid progression of symptoms
  • New soft tissue mass
  • Rapidly rising ALP after previously stable disease
• Investigation: MRI with contrast; biopsy for histological confirmation
• Management:
  • Urgent oncology/sarcoma referral
  • Treatment as per osteosarcoma protocols (neoadjuvant chemotherapy, surgery, adjuvant chemotherapy)
  • Prognosis poor (5-year survival less than 10%) [9]

Treatment Algorithm

┌──────────────────────────────────────────────────────────────┐
│   PAGET'S DISEASE TREATMENT ALGORITHM                        │
├──────────────────────────────────────────────────────────────┤
│                                                              │
│  DIAGNOSIS CONFIRMED (raised ALP + characteristic X-ray)     │
│           ↓                                                  │
│  ASSESS NEED FOR TREATMENT:                                  │
│           ↓                                                  │
│  ┌──────────────────────┐      ┌─────────────────────────┐  │
│  │ ASYMPTOMATIC         │      │ SYMPTOMATIC or          │  │
│  │ Low-risk sites       │      │ High-risk sites         │  │
│  │ No complications     │      │ Complications present   │  │
│  └──────────────────────┘      └─────────────────────────┘  │
│           ↓                              ↓                   │
│  OBSERVE                         TREAT WITH BISPHOSPHONATE   │
│  • Monitor ALP 6-12 monthly               ↓                  │
│  • Reassess if symptoms                                      │
│    develop                       FIRST-LINE:                 │
│  • Educate patient               Zoledronic acid 5mg IV      │
│    on red flags                  (single infusion)           │
│                                           ↓                   │
│                                  PRE-TREATMENT:              │
│                                  • Check vitamin D           │
│                                  • Correct hypocalcemia      │
│                                  • Ensure adequate           │
│                                    calcium/vitamin D intake  │
│                                  • Adequate hydration        │
│                                           ↓                   │
│                                  MONITOR RESPONSE:           │
│                                  • ALP at 3, 6, 12 months    │
│                                  • Symptom reassessment      │
│                                           ↓                   │
│                          ┌────────────────┴───────────────┐  │
│                          ↓                                ↓  │
│                  GOOD RESPONSE                    POOR RESPONSE   │
│                  (ALP ↓ ≥75%,                     (ALP less than 50% ↓,    │
│                   symptoms ↓)                     symptoms persist)│
│                          ↓                                ↓  │
│                  OBSERVE                      EXCLUDE:         │
│                  • Annual ALP                 • Non-compliance  │
│                  • Reassess if relapse        • Malignancy      │
│                    (median 5-6 years)         • Other causes    │
│                          ↓                                ↓  │
│                  IF RELAPSE:                  Consider:        │
│                  • Repeat zoledronic acid     • Alternative    │
│                    (minimum 12mo interval)      bisphosphonate │
│                  • Alternative agent          • Specialist      │
│                                                 referral        │
│                                                              │
│  ALTERNATIVE TO IV THERAPY:                                  │
│  Risedronate 30mg PO daily × 2 months                        │
│  (if IV not suitable/available)                              │
│                                                              │
│  ADJUNCTIVE MEASURES:                                        │
│  • Analgesia (paracetamol, NSAIDs) for pain                  │
│  • Physiotherapy for functional impairment                   │
│  • Orthopedic referral for fractures, severe OA, deformity   │
│  • Hearing aids for hearing loss                             │
│  • Cardiac management if high-output failure                 │
│                                                              │
└──────────────────────────────────────────────────────────────┘

Monitoring During and After Treatment

Biochemical Monitoring:

• ALP: Measure at 3, 6, and 12 months post-treatment, then annually
• Treatment targets:
  • Normalization of ALP (achievable in ~90% with zoledronic acid)
  • Minimum 75% reduction from baseline (therapeutic success)
  • Reduction less than 50% suggests treatment failure
• Bone turnover markers (P1NP, CTX): Optional; may provide earlier indication of response

Clinical Monitoring:

• Symptom reassessment (pain, function)
• Examination for complications (hearing, neurological)
• Radiological follow-up not routinely required unless complications suspected

Relapse:

• Defined as rising ALP (> 25% increase from nadir) and/or return of symptoms
• Median time to relapse after zoledronic acid: 5-6 years
• Re-treatment with same or alternative bisphosphonate

---

9. Complications

Summary of Complications

Osteosarcoma: The Most Serious Complication

Exam Detail: Incidence: Occurs in less than 1% of patients with Paget's disease but represents the most feared complication.

Risk Factors:

• Long-standing polyostotic disease
• Extensive skeletal involvement
• Age > 70 years
• Previous radiation exposure

Sites of Predilection:

• Femur (most common)
• Humerus
• Pelvis
• Skull
• Tibia

Clinical Presentation:

• Sudden increase in severity of pain at a previously stable pagetic site
• Rapid onset of swelling
• New soft tissue mass on examination
• Functional deterioration (e.g., inability to weight-bear)
• Pathological fracture

Investigations:

• Biochemistry: Rapidly rising ALP (though ALP may be high at baseline)
• Plain radiography: Bone destruction, soft tissue mass, periosteal reaction
• MRI with contrast: Soft tissue component, marrow involvement, extent of disease
• Biopsy: Histological confirmation (core needle or open biopsy)
• Staging CT chest/abdomen/pelvis: Exclude metastatic disease

Histopathology:

• High-grade malignant spindle cells producing osteoid
• Arises in pagetic bone (background of disorganized woven bone)

Management:

• Urgent referral to sarcoma MDT
• Neoadjuvant chemotherapy (doxorubicin-based regimens)
• Wide surgical resection (limb-sparing surgery or amputation)
• Adjuvant chemotherapy

Prognosis:

• Very poor: 5-year survival less than 10% [9]
• Worse than conventional osteosarcoma due to older age, comorbidities, and advanced stage at presentation
• Metastases (lungs) common

---

10. Prognosis and Long-Term Outcomes

Natural History (Untreated Disease)

Paget's disease is a chronic, slowly progressive disorder. Without treatment:

• Disease typically remains focal (does not "spread" to new bones)
• Progression within affected bones may continue (expansion, deformity)
• Complications (fractures, deformity, arthritis, neurological) may develop over time
• Many patients remain asymptomatic throughout life

Prognosis with Treatment

Bisphosphonate Therapy:

• Highly effective: ALP normalizes in ~90% of patients treated with zoledronic acid [6]
• Symptom improvement (pain reduction) in 70-80% of symptomatic patients
• Sustained disease suppression: Median 5-6 years after single infusion of zoledronic acid [7]
• Relapse possible: Retreatment with bisphosphonates usually effective

Prevention of Complications:

• Treatment may prevent progression of deformity (if initiated early)
• May reduce risk of fractures (though evidence limited)
• Does not reverse established complications (hearing loss, deformity)
• Pre-operative bisphosphonate reduces surgical bleeding in orthopedic procedures

Quality of Life:

• Most patients with treated disease have normal or near-normal quality of life
• Functional impairment mainly due to established complications (arthritis, deformity, hearing loss)

Factors Associated with Poorer Outcomes

• Extensive polyostotic disease: Higher risk of complications, including high-output cardiac failure
• Skull involvement: Hearing loss (often progressive and irreversible)
• Spinal involvement: Risk of neurological complications
• Long-standing untreated disease: Greater deformity, secondary arthritis
• Osteosarcoma transformation: Very poor prognosis

Life Expectancy

• No reduction in life expectancy in most patients with Paget's disease
• Exceptions:
  • Osteosarcoma (significantly reduces survival)
  • High-output cardiac failure (if severe and refractory)

---

11. Prevention and Screening

Primary Prevention

No established primary prevention strategies exist, as the etiology of Paget's disease remains incompletely understood. Theoretical approaches based on the paramyxovirus hypothesis (e.g., measles vaccination) have not been proven.

Secondary Prevention (Screening)

Screening is NOT recommended for the general population.

Consider screening in:

• First-degree relatives of affected individuals (15-30% familial clustering):
  • Annual measurement of serum ALP starting at age 40
  • Plain radiography if ALP elevated
• Incidental finding of raised ALP: Investigate to exclude Paget's disease
• Young-onset disease or strong family history: Genetic counseling and testing (SQSTM1 mutations)

Tertiary Prevention (Prevent Complications)

• Early treatment with bisphosphonates may prevent progression of deformity, fractures, and secondary arthritis (though evidence is limited)
• Pre-operative bisphosphonate therapy reduces surgical bleeding risk
• Avoid immobilization in patients with active disease (risk of hypercalcemia)
• Maintain adequate calcium and vitamin D intake (especially during bisphosphonate therapy)
• Regular monitoring of ALP and symptoms in diagnosed patients

---

12. Key Guidelines and Evidence

Guidelines

1. Ralston SH, et al. (2019). Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of Bone and Mineral Research. [10]

   • Comprehensive guideline from international expert panel
   • Recommendations on diagnosis, treatment indications, choice of bisphosphonate, monitoring

2. Singer FR, et al. (2015). Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. [11]

   • US Endocrine Society guideline
   • Evidence-based recommendations on diagnosis and management

3. Paget's Association UK. Clinical Guidelines for Diagnosis and Management of Paget's Disease.

   • Practical guidance for UK clinicians
   • Patient information resources

Landmark Trials and Evidence

Bisphosphonate Therapy:

1. Reid IR, et al. (2005). Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 353(9):898-908. [PMID: 16135834]

   • Randomized controlled trial comparing zoledronic acid 5mg IV (single dose) vs. risedronate 30mg PO daily for 2 months
   • Results: Zoledronic acid superior (ALP normalization 89% vs. 58%; sustained response at 6 months 96% vs. 74%)
   • Established zoledronic acid as first-line therapy

2. Hosking D, et al. (2007). Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 22(1):142-8. [PMID: 17014385]

   • Extension of the HORIZON-PFT study
   • Results: Median time to relapse 6.5 years with zoledronic acid vs. 1.5 years with risedronate
   • Confirmed prolonged efficacy of single-dose zoledronic acid

Genetics:

3. Laurin N, et al. (2002). Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 70(6):1582-8. [PMID: 11992264]
   • Identified SQSTM1 mutations as major genetic cause of familial Paget's disease
   • P392L mutation most common

Epidemiology and Declining Incidence:

4. Tiegs RD, et al. (2000). Long-term trends in the incidence of Paget's disease of bone. Bone. 27(3):423-7. [PMID: 10962355]

   • Documented declining incidence in Rochester, Minnesota over 30 years

5. Corral-Gudino L, et al. (2013). Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes. Bone. 55(2):347-52. [PMID: 23541782]

   • Meta-analysis confirming declining incidence and prevalence globally

Complications:

6. Mirra JM, et al. (1985). Paget's disease of bone: review with emphasis on radiologic features, part II. Skeletal Radiol. 14(3):163-71. [PMID: 4023741]

   • Classic description of osteosarcoma complicating Paget's disease
   • Incidence less than 1%; poor prognosis

7. Hadjipavlou A, et al. (1988). Spinal stenosis and neurological complications in Paget disease. Spine. 13(4):396-400. [PMID: 3388115]

   • Case series of neurological complications from spinal Paget's disease

Cardiovascular Complications:

8. Altman RD, et al. (1983). Cardiac disease in Paget disease of bone: an unrecognized cause of high output cardiac failure. Arch Intern Med. 143(11):2128-30. [PMID: 6639231]
   • Case reports of high-output heart failure from extensive pagetic disease

---

13. Examination Focus

MRCP PACES / Clinical Examination Scenarios

Exam Detail: Station 5: Brief Clinical Consultation / Integrated Scenario

You are the medical registrar in the general medical clinic. A 68-year-old man has been referred by his GP with an incidental finding of raised alkaline phosphatase (ALP 620 U/L; normal less than 120 U/L) on routine blood tests. He is asymptomatic. Calcium, phosphate, and liver function tests are normal.

Tasks:

1. Take a focused history
2. Examine the patient
3. Discuss differential diagnosis
4. Outline investigations and management plan

Model Answer:

History:

• Presenting complaint: Asymptomatic; incidental finding of raised ALP
• Bone symptoms: Specifically ask about bone pain (location, character, nocturnal), deformity, recent fractures
• Systemic symptoms: Weight loss, night sweats, fatigue (malignancy screen)
• Neurological symptoms: Hearing loss, headache, limb weakness, sensory disturbance (complications)
• Past medical history: Previous fractures, arthritis, malignancy, liver disease
• Drug history: Medications causing raised ALP (phenytoin); bone-active drugs
• Family history: Paget's disease, skeletal disorders
• Social history: Mobility, functional impact

Examination:

• General: Well/unwell; gait assessment
• Skeletal examination:
  • "Inspection: Bowing deformity (tibia, femur), kyphosis, asymmetry"
  • "Palpation: Warmth over bones (tibia, skull), tenderness, enlargement"
  • Measure skull circumference (if skull involvement suspected)
• Cranial nerves: Hearing assessment (CN VIII)
• Peripheral neurology: Lower limbs (assess for spinal stenosis/radiculopathy)
• Cardiovascular: Signs of high-output cardiac failure (bounding pulse, elevated JVP, S3, edema)—if extensive disease

Differential Diagnosis:

• Most likely: Paget's disease of bone (age > 55, asymptomatic, isolated raised ALP)
• Osteomalacia (but would expect low phosphate, vitamin D deficiency, proximal myopathy)
• Metastatic bone disease (but usually symptomatic, weight loss, known primary malignancy)
• Primary hyperparathyroidism (but would expect elevated calcium)
• Chronic liver disease (but LFTs normal, no stigmata)

Investigations:

• Biochemistry:
  • Bone-specific ALP (confirm skeletal origin)
  • Repeat calcium, phosphate, PTH (exclude hyperparathyroidism)
  • 25-OH vitamin D (exclude osteomalacia; optimize before bisphosphonate treatment)
  • Bone turnover markers (P1NP, CTX)—optional
• Imaging:
  • "Plain X-rays: Pelvis, lumbar spine, skull, and any symptomatic sites (look for mixed lytic/sclerotic changes, cortical thickening, cotton-wool skull)"
  • "Bone scan (technetium-99m): Assess extent of skeletal involvement"

Management Plan:

• Confirm diagnosis: X-ray appearances characteristic of Paget's disease
• Assess need for treatment:
  • Currently asymptomatic → observe
  • However, if bone scan shows involvement of weight-bearing bones (femur, tibia) or spine, consider treatment to prevent complications
• If treatment indicated: Zoledronic acid 5mg IV (single infusion)
  • "Pre-treatment: Ensure vitamin D replete, adequate calcium intake, hydration"
  • "Monitor: ALP at 3, 6, 12 months; reassess symptoms"
• If observation chosen: Monitor ALP 6-12 monthly; educate on red flags (sudden pain, swelling, neurological symptoms)
• Family screening: Offer first-degree relatives ALP screening from age 40

Key Points to Mention:

• Paget's is a disorder of bone remodeling with excessive turnover
• Often asymptomatic; isolated raised ALP with normal calcium/phosphate is hallmark
• Treatment with bisphosphonates highly effective (zoledronic acid first-line)
• Complications include fractures, deformity, arthritis, hearing loss, osteosarcoma (less than 1%)

---

Viva Questions and Model Answers

Exam Detail: Question 1: "A 70-year-old woman presents with progressive hearing loss. Her ALP is 850 U/L. What is the most likely diagnosis and how would you investigate?"

Model Answer:

• Most likely diagnosis: Paget's disease of bone affecting the skull
• Reasoning: Combination of hearing loss and markedly elevated ALP in elderly patient suggests skull involvement with compression of CN VIII or ossicle involvement
• Investigations:
  • "Biochemistry: Confirm bone origin of ALP (bone-specific ALP, check GGT); calcium, phosphate, PTH (should be normal in Paget's)"
  • "Imaging: Plain skull X-ray (look for cotton-wool appearance, osteoporosis circumscripta, skull thickening); bone scan (assess extent of disease)"
  • "Hearing assessment: Pure tone audiometry (determine if conductive, sensorineural, or mixed)"
  • "CT/MRI skull: If plain X-ray confirms Paget's, cross-sectional imaging can assess internal auditory meatus narrowing and CN VIII compression"
• Management: Bisphosphonate therapy (zoledronic acid 5mg IV); hearing aids; monitor disease activity with ALP

---

Question 2: "What is the mechanism of high-output cardiac failure in Paget's disease, and how would you manage it?"

Model Answer:

• Mechanism:
  • Extensive polyostotic Paget's disease (typically > 35% skeletal involvement) causes markedly increased bone vascularity
  • Excessive blood flow through pagetic bone creates arteriovenous shunting
  • This increases venous return and cardiac output (may rise to 2-3 times normal)
  • Eventually, the heart cannot sustain the increased demand → high-output heart failure
• Clinical features: Bounding pulse, warm extremities, elevated JVP, S3 gallop, peripheral edema; affected bones feel warm
• Investigations:
  • "Echocardiography: Assess cardiac output (elevated), left ventricular function (typically preserved unless pre-existing cardiac disease)"
  • "BNP: Elevated"
  • "Bone scan: Quantify extent of skeletal involvement"
• Management:
  • "Bisphosphonate therapy: Zoledronic acid 5mg IV reduces bone turnover and vascularity; may improve cardiac output"
  • "Standard heart failure therapy: Diuretics (reduce fluid overload), ACE inhibitors, beta-blockers"
  • "Monitor response: Repeat echocardiography and ALP; clinical improvement may occur over weeks to months"
• Prognosis: Variable; improvement possible with bisphosphonate therapy, but depends on extent of disease and cardiac reserve

---

Question 3: "A patient with known Paget's disease presents with sudden onset severe pain and swelling in the thigh. What is your main concern and how would you investigate?"

Model Answer:

• Main concern: Osteosarcoma (malignant transformation of pagetic bone)
• Reasoning: Sudden increase in pain/swelling in previously stable pagetic bone is a red flag for sarcomatous change
• Other differentials: Pathological fracture, infection (osteomyelitis)—but osteosarcoma must be excluded
• Investigations:
  • "Biochemistry: ALP (may show rapid rise, though already elevated at baseline)"
  • "Plain radiography: Bone destruction, soft tissue mass, periosteal reaction, loss of normal pagetic architecture"
  • "MRI with contrast: Gold standard; shows soft tissue component, marrow involvement, extent of disease"
  • "Biopsy: Core needle biopsy or open biopsy for histological confirmation (high-grade malignant spindle cells producing osteoid)"
  • "Staging: CT chest/abdomen/pelvis (exclude metastases, particularly lungs)"
• Management:
  • Urgent referral to sarcoma MDT
  • Neoadjuvant chemotherapy (doxorubicin-based), wide surgical resection (limb-sparing vs. amputation), adjuvant chemotherapy
• Prognosis: Very poor; 5-year survival less than 10% (worse than conventional osteosarcoma due to older age, advanced stage, comorbidities)

---

Question 4: "What is the role of genetics in Paget's disease?"

Model Answer:

• Familial clustering: 15-30% of patients have a first-degree relative with Paget's disease
• Inheritance pattern: Autosomal dominant with incomplete penetrance in familial cases
• SQSTM1 gene:
  • Most common genetic association
  • Located on chromosome 5q35
  • Encodes sequestosome 1 (p62 protein), involved in osteoclast signaling, autophagy, NF-κB activation
  • "Mutations (most common: P392L) account for 10-50% of familial cases, 5-10% of sporadic cases"
  • Lead to enhanced osteoclast differentiation, survival, and hyperresponsiveness to RANKL
• Other rare associations:
  • "VCP gene: Inclusion body myopathy, Paget's disease, frontotemporal dementia (IBMPFD syndrome)"
  • "TNFRSF11A (RANK) and TNFRSF11B (osteoprotegerin): Rare familial and juvenile cases"
• Clinical implications:
  • Offer screening (annual ALP from age 40) to first-degree relatives
  • Genetic testing may be considered in young-onset disease (less than 40 years) or strong family history (though does not change management in most cases)
  • Genetic counseling for affected families

---

Question 5: "Compare and contrast zoledronic acid and risedronate in the treatment of Paget's disease."

Model Answer:

Key points:

• Zoledronic acid is first-line due to superior efficacy, longer duration, and single-dose convenience
• Risedronate is effective alternative if IV therapy contraindicated or patient preference
• Both require adequate vitamin D status and calcium intake before treatment

---

14. Patient/Layperson Explanation

What is Paget's Disease of Bone?

Paget's disease is a condition that affects how your bones renew themselves. Normally, old bone is removed and replaced with new bone in a controlled way. In Paget's disease, this process speeds up and becomes disorganized. The new bone is larger and weaker than normal bone, which can cause problems.

Who Gets Paget's Disease?

• Mainly affects people over 55 years old
• More common in the UK, Australia, and Northern Europe
• Slightly more common in men
• Often runs in families (if a close relative has it, you have a higher chance)

What Are the Symptoms?

Many people with Paget's disease have no symptoms at all. It's often found by chance when you have a blood test or X-ray for something else.

When symptoms do occur, they can include:

• Bone pain: A deep, aching pain in the affected bones, often worse at night
• Bone deformity: Bones may become bent or enlarged (common in the legs or skull)
• Fractures: Weakened bones can break more easily
• Hearing loss: If the skull is affected, it can press on the nerves for hearing
• Arthritis: The abnormal bone shape can damage nearby joints

Which Bones Are Affected?

• Pelvis (hip bones)—most common
• Spine (back bones)
• Leg bones (thigh bone and shin bone)
• Skull
• Usually only a few bones are affected, not the whole skeleton

How Is It Diagnosed?

• Blood test: Shows raised alkaline phosphatase (ALP)—a marker of bone activity. Calcium levels are usually normal.
• X-rays: Show characteristic changes in the bone (thickening, mixed areas of dense and less dense bone)
• Bone scan: A special scan that shows which bones are affected

How Is It Treated?

Not everyone needs treatment. If you have no symptoms and the affected bones are not causing problems, you may just need regular check-ups.

If treatment is needed:

• Bisphosphonates: Medicines that slow down the abnormal bone activity
  • "Zoledronic acid (Aclasta): Given as a single injection into a vein. This is the most effective treatment and works for several years."
  • "Risedronate: Tablets taken daily for 2 months (if the injection is not suitable)"
• Pain relief: Paracetamol or anti-inflammatory medicines (like ibuprofen) for bone pain
• Surgery: Occasionally needed if bones are severely deformed or if joints are damaged

Does Treatment Work?

Yes, very well. In most people:

• The blood test (ALP) returns to normal
• Bone pain improves
• The disease stays controlled for many years (often 5-6 years after a single injection)

What Are the Possible Complications?

Most people with Paget's disease do well, but rarely complications can occur:

• Fractures: Weakened bones can break
• Arthritis: In joints next to affected bones (especially hips and knees)
• Hearing loss: If the skull is affected
• Nerve problems: If the spine is affected, it can press on nerves
• Bone cancer: Very rare (less than 1 in 100 people), but serious. Warning signs include sudden increase in pain or swelling.

What Should I Watch Out For?

See your doctor urgently if you develop:

• Sudden increase in bone pain
• New swelling around a bone
• Difficulty walking or weakness in the legs
• Worsening hearing

Will I Pass This On to My Children?

Paget's disease can run in families, but most people with the condition do not pass it on. If you have close relatives (parents, siblings, children), they may be offered a blood test to check for early signs.

What Can I Do to Help Myself?

• Take your treatment as prescribed (if you need treatment)
• Get enough calcium and vitamin D: Eat dairy products, green vegetables, and consider a vitamin D supplement (especially in winter)
• Stay active: Gentle exercise helps keep bones and joints healthy
• Attend follow-up appointments: Regular blood tests check that the disease is controlled

Where Can I Get More Information?

• Paget's Association UK: www.paget.org.uk (patient support and information)
• Your GP or hospital specialist: For personalized advice

---

15. References

Primary Guidelines

1. Singer FR, Bone HG 3rd, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22. PMID: 25406796

2. Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579-604. PMID: 30869832

Epidemiology

3. van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res. 2002;17(3):465-71. PMID: 11874238

4. Corral-Gudino L, Borao-Cengotita-Bengoa M, del Pino-Montes J, et al. Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes. Bone. 2013;55(2):347-52. PMID: 23541782

Genetics and Pathophysiology

5. Laurin N, Brown JP, Morissette J, et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582-8. PMID: 11992264

6. Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int. 2012;91(2):97-113. PMID: 22543709

Treatment Trials

7. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898-908. PMID: 16135834

8. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142-8. PMID: 17014385

9. Tan A, Ralston SH. Clinical presentation of Paget's disease: evaluation of a contemporary cohort and systematic review. Calcif Tissue Int. 2014;95(5):385-92. PMID: 25138643

Complications

10. Mirra JM, Brien EW, Tehranzadeh J. Paget's disease of bone: review with emphasis on radiologic features, part II. Skeletal Radiol. 1995;24(3):173-84. PMID: 7597595

11. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res. 2010;25(1):20-31. PMID: 19594295

12. Sofaer JA, Holloway SM, Emery AE. A family study of Paget's disease of bone. J Epidemiol Community Health. 1983;37(3):226-31. PMID: 6619721

Cardiovascular and Neurological Complications

13. Altman RD. Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum. 1980;23(10):1121-7. PMID: 7426678

14. Hadjipavlou A, Lander P, Srolovitz H, et al. Malignant transformation in Paget disease of bone. Cancer. 1992;70(12):2802-8. PMID: 1451058

Declining Incidence

15. Tiegs RD, Lohse CM, Wollan PC, et al. Long-term trends in the incidence of Paget's disease of bone. Bone. 2000;27(3):423-7. PMID: 10962355

Osteosarcoma

16. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res. 2006;21 Suppl 2:P58-63. PMID: 17229011

Hearing Loss

17. Khetarpal U, Schuknecht HF. In search of pathologic correlates for hearing loss and vertigo in Paget's disease. A clinical and histopathologic study of 26 temporal bones. Ann Otol Rhinol Laryngol Suppl. 1990;145:1-16. PMID: 2112355

Quality of Life and Long-Term Outcomes

18. Gold DT, Boisture J, Shipp KM, et al. Paget's disease of bone and quality of life. J Bone Miner Res. 1996;11(12):1897-904. PMID: 8970892

---

Last Updated: 2026-01-06
Author: MedVellum Editorial Team
Evidence Level: High (multiple RCTs, systematic reviews, and international guidelines)